TWI798334B - Erbb/btk抑制劑 - Google Patents
Erbb/btk抑制劑 Download PDFInfo
- Publication number
- TWI798334B TWI798334B TW108101860A TW108101860A TWI798334B TW I798334 B TWI798334 B TW I798334B TW 108101860 A TW108101860 A TW 108101860A TW 108101860 A TW108101860 A TW 108101860A TW I798334 B TWI798334 B TW I798334B
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- egfr
- mmol
- alkyl
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/02—Formic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
- C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Polarising Elements (AREA)
- Glass Compositions (AREA)
- Electronic Switches (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018074791 | 2018-01-31 | ||
| WOPCT/CN2018/074791 | 2018-01-31 | ||
| ??PCT/CN2018/074791 | 2018-01-31 | ||
| ??PCT/CN2018/118569 | 2018-11-30 | ||
| WOPCT/CN2018/118569 | 2018-11-30 | ||
| CN2018118569 | 2018-11-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201940472A TW201940472A (zh) | 2019-10-16 |
| TWI798334B true TWI798334B (zh) | 2023-04-11 |
Family
ID=67478612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW108101860A TWI798334B (zh) | 2018-01-31 | 2019-01-17 | Erbb/btk抑制劑 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11007198B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4356975A3 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7427597B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20250046340A (cg-RX-API-DMAC7.html) |
| CN (4) | CN111909131B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2019215538B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3086616A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3746424T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2977484T3 (cg-RX-API-DMAC7.html) |
| MX (2) | MX2020007947A (cg-RX-API-DMAC7.html) |
| PT (1) | PT3746424T (cg-RX-API-DMAC7.html) |
| RU (1) | RU2764069C1 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI798334B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019149164A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI798334B (zh) * | 2018-01-31 | 2023-04-11 | 大陸商迪哲(江蘇)醫藥股份有限公司 | Erbb/btk抑制劑 |
| US11896597B2 (en) * | 2018-01-31 | 2024-02-13 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | ErbB/BTK inhibitors |
| US12157730B2 (en) | 2019-03-19 | 2024-12-03 | Voronoi Inc. | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component |
| JP7109013B2 (ja) | 2019-03-19 | 2022-07-29 | ボロノイ インコーポレイテッド | ヘテロアリール誘導体、ヘテロアリール誘導体の生成方法、およびヘテロアリール誘導体を有効成分として含む医薬組成物 |
| WO2021104305A1 (zh) * | 2019-11-26 | 2021-06-03 | 上海翰森生物医药科技有限公司 | 含氮多环类衍生物抑制剂、其制备方法和应用 |
| CN111057021B (zh) * | 2019-12-11 | 2023-05-23 | 中国药科大学 | 均三嗪类化合物及其制备方法和用途 |
| AU2021205834A1 (en) * | 2020-01-07 | 2022-08-25 | Dana-Farber Cancer Institute, Inc. | Cyano-pyrimidine inhibitors of EGFR/HER2 |
| CN111470998B (zh) * | 2020-06-28 | 2020-09-25 | 上海皓元生物医药科技有限公司 | 用于合成喜树碱衍生物的中间体及其制备方法和用途 |
| CN112409281B (zh) * | 2020-08-20 | 2022-11-18 | 上海大学 | (e)-3-(3-氯-2-氟-6-(1h-四氮唑-1-基)苯基)丙烯酸的合成方法 |
| CN112679446A (zh) * | 2020-10-26 | 2021-04-20 | 都创(上海)医药科技有限公司 | 一种合成反式-3-(3-氯-2-氟-6-(1h-四氮唑-1-基)苯基)丙烯酸的方法 |
| CN116670127A (zh) * | 2021-03-30 | 2023-08-29 | 贝达药业股份有限公司 | Egfr抑制剂及其组合物和用途 |
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| BR112023025660A2 (pt) * | 2021-07-02 | 2024-02-27 | Aldeyra Therapeutics Inc | Compostos de captação de aldeído heterocíclicos e usos dos mesmos |
| AU2022324410A1 (en) * | 2021-08-02 | 2024-01-18 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Novel pharmaceutical salts and polymorphic forms of an erbb and btk inhibitor |
| CN115181093B (zh) * | 2022-08-01 | 2023-04-25 | 重庆医科大学 | Sunvozertinib中间体的制备方法 |
| EP4731307A1 (en) | 2023-06-23 | 2026-04-29 | Assia Chemical Industries Ltd. | Solid state forms of sunvozertinib |
| WO2025247783A1 (en) | 2024-05-29 | 2025-12-04 | Syngenta Crop Protection Ag | Pesticidally active dihydro-benzoxazinone compounds |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017114500A1 (zh) * | 2015-12-31 | 2017-07-06 | 恩瑞生物医药科技(上海)有限公司 | 丙烯酰苯胺衍生物、其制备方法及其药学上的应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100799534B1 (ko) * | 2004-02-27 | 2008-01-31 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 신규 피리딘 유도체 및 피리미딘 유도체(1) |
| AU2009262068C1 (en) * | 2008-06-27 | 2015-07-02 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| HUE033177T2 (en) * | 2012-01-17 | 2017-11-28 | Astellas Pharma Inc | Pyrazine carboxamide compound |
| JP6317320B2 (ja) * | 2012-03-15 | 2018-04-25 | セルジーン シーエーアール エルエルシー | 上皮成長因子受容体キナーゼ阻害剤の塩 |
| JP6469567B2 (ja) * | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Egfr発動性がんの細胞増殖阻害用化合物 |
| CN104854101B (zh) | 2012-11-06 | 2018-05-01 | 上海复尚慧创医药研究有限公司 | Alk激酶抑制剂 |
| JP6510510B2 (ja) * | 2013-07-11 | 2019-05-08 | ベータ ファーマシューティカルズ カンパニー リミテッド | プロテインチロシンキナーゼモジュレーター及び使用方法 |
| CA2920534A1 (en) | 2013-08-12 | 2015-02-19 | Pharmacyclics Llc | Methods for the treatment of her2 amplified cancer |
| CN105384694B (zh) * | 2014-08-22 | 2020-09-04 | 四川海思科制药有限公司 | 一种取代的氨基嘧啶衍生物及其制备方法和药物用途 |
| CN106883213B (zh) * | 2015-12-15 | 2021-04-20 | 合肥中科普瑞昇生物医药科技有限公司 | 一种egfr和alk激酶的双重抑制剂 |
| CN106905245B (zh) * | 2015-12-23 | 2021-06-25 | 正大天晴药业集团股份有限公司 | 2,4-二取代的嘧啶类化合物 |
| CN106083736A (zh) * | 2016-06-21 | 2016-11-09 | 郑州泰基鸿诺医药股份有限公司 | 一种嘧啶类化合物、egfr抑制剂及其应用 |
| TWI798334B (zh) * | 2018-01-31 | 2023-04-11 | 大陸商迪哲(江蘇)醫藥股份有限公司 | Erbb/btk抑制劑 |
| KR102782739B1 (ko) * | 2018-03-13 | 2025-03-20 | 보로노이 주식회사 | 2,4,5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 |
-
2019
- 2019-01-17 TW TW108101860A patent/TWI798334B/zh active
- 2019-01-28 CN CN202010660882.XA patent/CN111909131B/zh active Active
- 2019-01-28 PT PT197482599T patent/PT3746424T/pt unknown
- 2019-01-28 KR KR1020257009058A patent/KR20250046340A/ko active Pending
- 2019-01-28 ES ES19748259T patent/ES2977484T3/es active Active
- 2019-01-28 RU RU2020127393A patent/RU2764069C1/ru active
- 2019-01-28 CA CA3086616A patent/CA3086616A1/en active Pending
- 2019-01-28 WO PCT/CN2019/073355 patent/WO2019149164A1/en not_active Ceased
- 2019-01-28 MX MX2020007947A patent/MX2020007947A/es unknown
- 2019-01-28 EP EP24161138.3A patent/EP4356975A3/en active Pending
- 2019-01-28 EP EP19748259.9A patent/EP3746424B1/en active Active
- 2019-01-28 CN CN202610219448.5A patent/CN122464860A/zh active Pending
- 2019-01-28 KR KR1020207025029A patent/KR102786279B1/ko active Active
- 2019-01-28 CN CN202010659802.9A patent/CN111747934A/zh active Pending
- 2019-01-28 DK DK19748259.9T patent/DK3746424T3/da active
- 2019-01-28 JP JP2020541535A patent/JP7427597B2/ja active Active
- 2019-01-28 CN CN201980006427.3A patent/CN111587244A/zh active Pending
- 2019-01-28 AU AU2019215538A patent/AU2019215538B2/en active Active
-
2020
- 2020-06-24 US US16/910,208 patent/US11007198B2/en active Active
- 2020-07-28 MX MX2023010411A patent/MX2023010411A/es unknown
-
2021
- 2021-04-07 US US17/224,121 patent/US11504375B2/en active Active
-
2023
- 2023-04-06 AU AU2023202151A patent/AU2023202151B2/en active Active
- 2023-10-19 JP JP2023180451A patent/JP7738619B2/ja active Active
-
2025
- 2025-09-02 JP JP2025145276A patent/JP2025179139A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017114500A1 (zh) * | 2015-12-31 | 2017-07-06 | 恩瑞生物医药科技(上海)有限公司 | 丙烯酰苯胺衍生物、其制备方法及其药学上的应用 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111909131B (zh) | Erbb/btk抑制剂 | |
| CN113272301A (zh) | 杂环类化合物、中间体、其制备方法及应用 | |
| CN112771027A (zh) | 溶血磷脂酸受体拮抗剂及其制备方法 | |
| CN108069976A (zh) | 一种含氮大环类化合物、其制备方法、药物组合物及应用 | |
| HK40037843A (en) | Erbb/btk inhibitors | |
| HK40037844A (en) | Erbb/btk inhibitors | |
| HK40037844B (en) | Erbb/btk inhibitors | |
| HK40027059A (en) | Erbb/btk inhibitors | |
| US11896597B2 (en) | ErbB/BTK inhibitors | |
| HK40109818A (en) | Erbb/btk inhibitors | |
| HK40127584A (en) | Pcsk9 inhibitors and methods of use thereof | |
| HK40041774A (en) | Lysophosphatidic acid receptor antagonists and preparation method therefor | |
| BR112020015726B1 (pt) | Composto, composição farmacêutica compreendendo o mesmo e seus usos na fabricação de medicamentos | |
| HK40068840B (zh) | 稠合吡啶酮类化合物及其制备方法和应用 | |
| HK40039346A (en) | Erbb/btk inhibitors | |
| HK40039346B (en) | Erbb/btk inhibitors | |
| HK40009971A (en) | 1,3-thiazol-2-yl substituted benzamides | |
| HK40068840A (en) | Fused pyridone compound, preparation method therefor and use | |
| HK40009971B (en) | 1,3-thiazol-2-yl substituted benzamides | |
| HK40048952A (en) | Heterocyclic compound, intermediate, preparation method therefor and application thereof |